Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic markers for prediction of treatment outcomes in ovarian cancer.

The pharmacogenomics journal - 1 Oct 2014

Caiola E, Broggini M, Marabese M

Abstract excerpt

Drug resistance in epithelial ovarian cancer (EOC) limits the efficacy of therapies for this malignancy. This phenomenon might be partially explained by strong inter-individual genomic heterogeneity. Single nucleotide polymorphisms (SNPs) located in specific genes involved in platinum-based drugs inactivation and the metabolism and extrusion of taxanes could be relevant in terms of drugs response prediction. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor
Share to Genetic Variation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Polymorphism, Single Nucleotide

Share to Treatment Outcome

Source

Identifiers

PMID: 25001881
DOI: 10.1038/tpj.2014.32

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic markers for prediction of treatment outcomes in ovarian cancer.PMID 25001881Read ↗

Pharmacogenomics of taxane/platinum therapy in ovarian cancer.Semantic proximity Read ↗

Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis.Semantic proximity Read ↗

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsSemantic proximity Read ↗

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.Semantic proximity Read ↗

‘Genetic profiling’ and ovarian cancer therapy (Review)Semantic proximity Read ↗

Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.Semantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

[ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].Semantic proximity Read ↗

Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic OriginsSemantic proximity Read ↗

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.Semantic proximity Read ↗

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targetsSemantic proximity Read ↗

Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.